@FiercePharma: Top-read on FP this weekend: Why does #Sovaldi cost $84,000? Gilead being pressed hard for an answer. Story | Follow @FiercePharma
@TracyStaton: ICYMI, the latest in the #Sovaldi pricing squabble: Congress wants to get involved. More | Follow @TracyStaton
@EricPFierce: How much are the big dogs of Big Pharma paid? A lot. See the top 15 highest paid CEOs here. Report | Follow @EricPFierce
@CarlyHFierce: ICYMI Friday: Italian officials probe Novartis for possible flu vaccine pricing fraud. News | Follow @CarlyHFierce
> Denmark's Lundbeck wrapped up its tender offer for Chelsea Therapeutics, which will bring along its recently FDA-approved orphan drug Northera. Report
> The Pennsylvania Supreme Court tossed out a $28 million award against Bristol-Myers Squibb ($BMY) in a drug-pricing dispute. Report
> Pfizer ($PFE) won the nod for broader use of its Prevnar 13 vaccine in Japan, in adults 65 years and older, a key market in a country with an aging population. Report
> Pfizer ($PFE) lost a fight to exclude its Depo Testosterone product from a consolidation of all lawsuits over testosterone treatments. Report
> Regulators are planning to overhaul India's drug pricing structure, and they're looking at pricing models in other countries for ideas. Report
Medical Device News
@FierceMedDev: Apple, Google stalk wearable med tech with glucose monitoring up first. Feature | Follow @FierceMedDev
@StacyALawrence: AbbVie says Shire has spurned three buyout offers, won't rule out new bid. Story from Friday | Follow @StacyALawrence
@MichaelGFierce: UPenn team combats Parkinson's with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce
@EmilyWFierce: Medtronic reveals cyberattack and lost patient data in latest regulatory filing. More | Follow @EmilyWFierce
> In test of FDA guidelines, medical mobile app Abriiz escapes scrutiny. News
> FDA to stop regulating some medical device software. More
Biotech News
@FierceBiotech: Roche partners with Versant on a new build-to-sell biotech on MS. More | Follow @FierceBiotech
@JohnCFierce: FDA review red-flags AstraZeneca's case for ovarian cancer drug olaparib. Story | Follow @JohnCFierce
@DamianFierce: Amazing first line of a BIO 2014 email: "As you have probably heard Steve Burrill is unable to attend BIO this year." Yeah, I heard. | Follow @DamianFierce
@EmilyMFierce: Stem cell treatment for horses to be tried in humans. Story via BBC News | Follow @EmilyMFierce
> Beaten by rivals, Boehringer surrenders in hep C contest. More
> John Carroll wins the European Mediscience 'Commentator of the Year' award. Publisher's note
> Gelesis declares a weight-loss victory, but a critic pans new therapy. Story
CRO News
> Teva settles with Catalent, Perrigo in inhaler patent suit. Item
> Parexel rolls out new eClinical tech to speed up study start-up. Story
> Simbec buys its way into late-stage R&D with Orion deal. Article
> Japanese CRO taps BBK for a U.S. joint venture. News
> Quintiles partners up to flex its commercial muscles. More
> BioClinica dives into adaptive trials with latest buy. Report
Biotech IT News
> Survey: Biopharma still reliant on paper, email for sharing TMFs. Item
> USC in talks to buy or affiliate with Scripps. Story
> AstraZeneca opens up compound library to select academics. More
> FDA's long-awaited Twitter guidance gives biopharma certainty and constraints. Article
> Big Pharma consortium adds redaction of trial information to list of initiatives. News
> Tech vendors flock to DIA to show off new software. Report
And Finally... A federal judge upheld New York City's policy of barring unimmunized children from school when another student is ill with a vaccine-preventable disease. Report